We are live on ! Find out more
CCM

Consonance Capital Management Portfolio holdings

AUM $7.28M
1-Year Est. Return 43.59%
This Fund
S&P 500
This Quarter Est. Return
+39.83%
1 Year Est. Return
-43.59%
3 Year Est. Return
+313.86%
5 Year Est. Return
+886.32%
10 Year Est. Return
–
AUM
$1.04B
AUM Growth
+$332M
Cap. Flow
+$148M
Cap. Flow %
14.28%
Top 10 Hldgs %
79.18%
Holding
32
New
10
Increased
5
Reduced
4
Closed
9

Top Buys

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$72.3M
2
AMRN
Amarin Corp
AMRN
+$69.1M
3
AKRX
Akorn Inc
AKRX
+$65.2M
4
UTHR icon
United Therapeutics
UTHR
+$48.1M
5
MD icon
Pediatrix Medical
MD
+$45.1M

Top Sells

Rank Stock Value
1
MDVN
MEDIVATION, INC.
MDVN
+$76.6M
2
ASRT
Assertio
ASRT
+$44.6M
3
PEN icon
Penumbra
PEN
+$40.7M
4
OFIX icon
Orthofix Medical
OFIX
+$26.3M
5
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$22.8M

Sector Composition

Rank Sector Weight
1 Healthcare 92.73%
2 Financials 1.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CLVS
1
DELISTED
Clovis Oncology, Inc.
CLVS
$127M 12.25%
3,531,487
+595,000
+20% +$12.8M
ARIA
2
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$119M 11.46%
8,695,742
-150,000
-2% -$1.51M
MNK
3
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$109M 10.48%
1,560,157
– –
UTHR icon
4
United Therapeutics
UTHR
$26.2B
$96.7M 9.31%
818,700
+400,000
+96% +$48.1M
AMRN
5
Amarin Corp
AMRN
$298M
$78.6M 7.57%
+1,232,619
New +$69.1M
TVTX icon
6
Travere Therapeutics
TVTX
$5.33B
$69M 6.65%
3,084,947
+385,000
+14% +$7.33M
HZNP
7
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$67.1M 6.45%
+3,698,903
New +$72.3M
AKRX
8
DELISTED
Akorn Inc
AKRX
$60M 5.77%
+2,200,000
New +$65.2M
IRWD icon
9
Ironwood Pharmaceuticals
IRWD
$614M
$52.3M 5.04%
3,936,068
-1,949,324
-33% -$22.8M
MD icon
10
Pediatrix Medical
MD
$2.17B
$43.7M 4.21%
+660,000
New +$45.1M
ANIP icon
11
ANI Pharmaceuticals
ANIP
$1.83B
$43.3M 4.17%
653,258
-164,198
-20% -$10.3M
GMED icon
12
Globus Medical
GMED
$10.9B
$42M 4.04%
+1,860,000
New +$43.7M
MACK
13
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$37.8M 3.64%
+756,274
New +$31.4M
OFIX icon
14
Orthofix Medical
OFIX
$477M
$27.1M 2.61%
634,496
-590,000
-48% -$26.3M
MYGN icon
15
Myriad Genetics
MYGN
$507M
$17.5M 1.68%
+850,000
New +$21.6M
EHTH icon
16
eHealth
EHTH
$43.8M
$12.9M 1.25%
+1,154,711
New +$13.6M
HSTM icon
17
HealthStream
HSTM
$824M
$9.41M 0.91%
+340,847
New +$8.81M
ADMA icon
18
ADMA Biologics
ADMA
$2.01B
$9.22M 0.89%
1,273,933
– –
VCEL icon
19
Vericel Corp
VCEL
$2.43B
$6.25M 0.6%
2,232,940
– –
ATRC icon
20
AtriCure
ATRC
$2.04B
$3.67M 0.35%
+231,926
New +$3.57M
BIOL
21
DELISTED
Biolase, Inc.
BIOL
$3.13M 0.3%
143
+42
+42% +$748K
SPNE
22
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
$2.66M 0.26%
262,934
+7,600
+3% +$78.5K
VCYT icon
23
Veracyte
VCYT
$4.77B
$1.26M 0.12%
165,825
– –
ASRT
24
DELISTED
Assertio
ASRT
– –
-37,922
Closed -$44.6M
AXGN icon
25
Axogen
AXGN
$2.2B
– –
-526,351
Closed -$3.62M
1
2

Similar funds

GPC
Garrison Point Capital Walnut Creek, California $6.82M AUM 21.38% 1-Year Est. Return
BPM
Bronson Point Management Fairfield, Connecticut $8.26M AUM 46.43% 1-Year Est. Return
TVPI
True Venture Partners IV Palo Alto, California $8.41M AUM 78.89% 1-Year Est. Return
DCI
Data Collective II Palo Alto, California $8.44M AUM 11.7% 1-Year Est. Return
TPMI
Tilden Park Management I New York $5.38M AUM 28.49% 1-Year Est. Return
TP
Truvvo Partners New York $5.22M AUM 13.74% 1-Year Est. Return
SCG
Siris Capital Group New York $9.42M AUM 42.79% 1-Year Est. Return
CVGI
Craft Ventures GP I San Francisco, California $9.51M AUM 95.77% 1-Year Est. Return

Consonance Capital Management's Q3 2016 Portfolio in Review

As of Q3 2016, Consonance Capital Management held 32 positions worth $1.04B, up 47% from $707M the previous quarter. Its ten largest holdings account for 79% of the portfolio.

Consonance Capital Management deployed $148M of net new capital in Q3 2016, opening 10 new positions and adding to 5 existing holdings. Its largest new stake was Horizon Therapeutics Public Limited Company Ordinary Shares: 3,698,903 shares worth $67.1M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 89% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Orthofix Medical, an estimated $26.3M trimmed.

  • Consonance Capital Management's largest Q3 2016 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 3,698,903 shares worth $67.1M.
  • Consonance Capital Management added most to United Therapeutics in Q3 2016, an estimated $48.1M increase.
  • Consonance Capital Management's biggest Q3 2016 reduction was Orthofix Medical, cutting an estimated $26.3M.
  • Consonance Capital Management fully exited MEDIVATION, INC. in Q3 2016, selling an estimated $76.6M.
  • Consonance Capital Management's ten largest holdings make up 79% of its $1.04B portfolio in Q3 2016.
  • Consonance Capital Management opened 10 new positions and closed 9 in Q3 2016.
  • Consonance Capital Management's portfolio value rose 47% quarter-over-quarter to $1.04B.

Based on Consonance Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.